Back to Stakeholders
Soneira is a private psychedelic biotech company developing synthetic ibogaine therapies for neuropsychiatric conditions, with a primary focus on traumatic brain injury (TBI). The company has raised $15 million from Sergey Brin's Catalyst4 investment vehicle and is working to advance the first FDA-approvable synthetic ibogaine candidate to clinical trials.
Drug Pipeline
1Synthetic Ibogaine (TBI Program)
IbogainePre-clinical
Synthetic ibogaine analog designed for cardiac safety and regulatory approvability, targeting traumatic brain injury.
Quick Facts
- Type
- Private Biotech
- Lead Stage
- Pre-clinical
- Website
- Visit